Key Highlights
- Eli Lilly and Company captures roughly 70 percent of the Medicare GLP-1 obesity and diabetes drug market.
- The program is reaching approximately 700,000 seniors.
- CEO David Ricks told CNBC the company's Medicare share is growing week on week.
- Lilly's oral GLP-1 pill Foundayo now captures roughly one-third of new oral GLP-1 patients.
A Dominant and Growing Medicare Position
Eli Lilly and Company captures roughly 70 percent of the surging Medicare GLP-1 obesity and diabetes drug market, with the program now reaching approximately 700,000 seniors, and CEO David Ricks telling CNBC in an interview the week of September 21, 2026 that the company's Medicare share is growing week on week. A share position this dominant within a specific, closely watched payer segment gives Lilly a significant advantage in an area of the GLP-1 market that has drawn intense scrutiny given the scale of the senior population eligible for coverage.
Foundayo's Role in the Oral GLP-1 Category
Lilly's oral GLP-1 pill, branded Foundayo, now captures roughly one-third of new oral GLP-1 patients, giving the company a meaningful foothold in the oral formulation segment of the category alongside its established injectable GLP-1 products. An oral pill option addresses a segment of patients who may prefer to avoid injections, potentially broadening Lilly's addressable patient population within the broader GLP-1 market beyond those already using injectable therapies.
Cost and Manufacturing Considerations
Related reporting indicates that US taxpayers and Medicare are covering roughly USD 195 per patient under the program, a figure that provides useful context for understanding the fiscal scale of Medicare's GLP-1 coverage given the roughly 700,000 seniors currently participating. Ricks also indicated Lilly is ramping up manufacturing, including a large-scale production facility, to meet the continued growth in Demand across both its Medicare-covered patient base and the broader GLP-1 market.
Where Things Stand
Eli Lilly's dominant and still-growing position within Medicare's GLP-1 market, reinforced by Foundayo's early traction in the oral segment, underscores the company's leading position in one of pharmaceutical's fastest-growing drug categories. Continued manufacturing expansion will likely be necessary for Lilly to sustain this share position as both Medicare enrollment and broader GLP-1 demand continue to grow.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...